Biotech Stocks Reviews
- Notes from Affimed’s KOL Call Discussing AACR NK+AFM13
Wed, Apr 14
Affimed(AFMD)hosted a callafter market today to discuss cbNK+AFM13 data presented at AACR. KOL from MD · more » - A Look At Essa & Jounce Preclinical Data at AACR ’21
Mon, Apr 12
A look at pre-clinical data that Jounce and Essa presented at AACR this past weekend. Jounce · more » - Affimed’s AACR Data Validates Bi-Specifics In NK Cell Combinations
Fri, Apr 9
Affimed (AFMD)released initial clinical datafrom the AFM13 + MD Anderson combo study at AACR this · more » - Novavax’s Upcoming Eventful Q2
Thu, Apr 8
Novavax (NVAX) has been one of the companies most affected by the March biotech decline. It is now · more » - Expectations Ahead of AACR 2021
Wed, Apr 7
The American Association for Cancer Research (AACR) annual meeting will be hosted this coming weekend · more » - 9Meters Announces Financing Amid Biotech Rout
Wed, Mar 31
9Meters (NMTR) announced a $30M raise this morning, selling 30M shares at $1/share. After this deal, · more » - Is Delcath’s Phase 3 Data Enough For The FDA?
Wed, Mar 31
Delcath (DCTH)released preliminary datafor their Phase 3 in metastatic ocular melanoma (mOM). The · more » - 9Meter’s NM-002 Showing Early Signs of PS Reduction
Tue, Mar 23
9Meters (NMTR) had their KOL call to give an update on theNM-002 program for short bowel syndrome (SBS). · more » - Expectations for MGTA-145 in Mobilizing Myeloma Patients for Transplant
Thu, Mar 18
Magenta presented data for their mobilizing agent MGTA-145 at the European Society for Blood and Marrow · more »